Please upgrade your browser

We built this website using the latest browser technologies to deliver the very best experience.

This makes the site run faster and easier to use. Unfortunately, your browser is out of date and will not support some of these technologies.

We recommend that you use a modern browser such as Google Chrome or Microsoft Edge to view this website.

Download Microsoft EdgeDownload Microsoft Edge

Accelerating discovery through NHS partnerships

Strategic Research Agreements

Sensyne Health collaborates with NHS Trusts under strategic research agreements (SRAs) to combine clinical artificial intelligence technology (Clinical AI) with ethically-sourced, anonymised patient data to help improve patient care, accelerate the discovery and development of new medicines and improve our understanding of disease and treatment.  

Our current SRA partnerships include:

We have also signed conditional strategic research agreements with George Eliot NHS Trust and Wye Valley NHS Trust and we are in discussions with a number of other NHS Trusts regarding similar agreements.

Ethical Data Usage

NHS Trusts that partner with us under these agreements are not restricted from using their patient data in any way, either locally or nationally. In fact, Sensyne Health is working to help NHS Trusts improve the quality and curation of the data that they have.

Sensyne Health’s collaborative model sees individual NHS Trusts retaining full control of patient data under these agreements. Any analysis by Sensyne Health must be:

Sensyne Health’s partnership approach, which is unique in the UK, is designed to ensure that the NHS, individual Trusts and their patients benefit from NHS data. The NHS Trusts we work with under these agreements own an equity stake in Sensyne Health and are entitled to receive a share of any revenues generated by Sensyne Health as a result of the commercialisation of research carried out on anonymised patient data pursuant to these agreements.

Supporting the UK Industrial Strategy in Life Sciences

Sensyne Health is a strong supporter of the Government’s efforts to develop a national approach to health data analysis and enable innovation that accelerates medical research and delivers patient benefit – as demonstrated by our SEND and GDm-Health technologies, which are already in use across multiple NHS Trusts.

We believe it is imperative that the UK retains its position as a leader in this rapidly developing sector.  NHS patient data is the best in the world because of the free, single provider healthcare system that we have in the UK. Clinical AI using anonymised patient data has the potential to lead to significant healthcare benefits, including improving patient outcomes and speeding up the medicine discovery and development process, ultimately alleviating pressure on the NHS.


We have prepared a list below of the most commonly asked questions about our Strategic Research Agreements with NHS Trusts:

What is your definition of ‘anonymised data’?
What is the process for accessing and anonymising patient data?
Who controls the patient data?
How does an NHS Trust transfer anonymised patient data to Sensyne Health?
What are Sensyne Health’s cyber security protections for the anonymised patient data?
Does Sensyne Health have access to patient identifiable data?
Will the Trust’s patient data be shared with your pharmaceutical clients?
Does Sensyne Health ever sell anonymised patient data to any third party?
What are the patient benefits that arise from the analysis of the anonymised patient data?
How can we be confident that our data is being used ethically and analysed in a secure environment?
What happens to the patient data once you have analysed it?
What are the research questions that Sensyne is currently working on with other NHS Trusts? i.e. What clinical areas are you focused on?
How does a partner Trust receive a royalty share?
How does this agreement align with the NHS England letter on exclusivity?
What types of data are required, is there a minimum number of records required?
Our Trust is also a customer of your digital health products group, how do you handle this data?
How will you interact with a Trust as part of an SRA? What processes do you have in place?
Can the partnership be leveraged to improve the care for patients?
What is the opportunity for Trusts to undertake novel research with Sensyne Health using Clinical AI?
Does Sensyne Health abide by the principles set out in the DHSC’s Guidance document: ‘Creating the right framework to realise the benefits for patients and the NHS where data underpins innovation’?